Daiichi Sankyo enrolls first patient in Eliminate-AF study

Daiichi Sankyo Inc. has enrolled the first patient for its Eliminate-AF study.
The company’s Eliminate-AF project – a multinational, randomized Phase 3 study – will explore efficacy for Lixiana, an oral, once-daily Xainhibitor edoxaban for use in fighting Vitamin K antagonists in patients with atrial fibrillation (AF) undergoing catheter ablation.
“Catheter ablation as a method of treating AF is more frequently performed in clinical practice due to its positive effect on AF-related symptoms and quality of life; however, it is associated with a significant thromboembolic risk during and shortly after the procedure,” Dr. Stefan Hohnloser, professor of Medicine and Cardiology at Goethe University in Frankfurt, Germany, said in a statement. Hohnloser is a principal study investigator.
He noted that the study has given the company insights into catheter ablation.
“Eliminate-AF will provide insights into the use of edoxaban for uninterrupted anticoagulation in patients undergoing catheter ablation, applying state-of-the-art treatment in accordance with the recent treatment guidelines,” Hohnloser said. “In this study, edoxaban will be used with the approved dosage regimen for stroke risk reduction in atrial fibrillation.”